GNS Genus Plc

RNS Number:3500L
Genus PLC
09 January 2008


For immediate release                                             9 January 2008



                                   Genus plc
                           ("Genus" or the "Company")


                           Appointment of New Adviser



Genus plc, a world leading animal genetics company, is pleased to announce that
it has appointed JPMorgan Cazenove as lead financial adviser and joint
stockbroker with immediate effect.


Following this appointment Genus' advisers and stockbrokers are as follows:

JPMorgan Cazenove (lead financial adviser and joint stockbroker)
Landsbanki (financial adviser and joint stockbroker)
Panmure Gordon (joint stockbroker)



For further information, please contact:

Genus plc                                           Tel: 01256 345970
Richard Wood, Chief Executive
Martin Boden, Finance Director

JPMorgan Cazenove Limited                           Tel: 020 7588 2828
David Clasen

Landsbanki Securities (UK) Limited                  Tel: 020 7426 9000
Shaun Dobson

Panmure Gordon (UK) Limited                         Tel: 020 7459 3600
Mark Lander

Buchanan Communications                             Tel: 020 7466 5000
Charles Ryland / Suzanne Brocks



About Genus


Genus sells added value products for livestock farming and food producers by
creating advances to animal breeding through biotechnology. Its non-Genetically
Modified Organism (GMO) technology is applicable across all livestock species
but is only commercialised by Genus in the bovine and porcine farming sectors.


Genus' worldwide sales are made in seventy countries under the trade marks "ABS"
(dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals
with superior genetics to those animals currently in production. Customers use
Genus genetics in their herds to produce offspring with greater production
efficiency, milk and meat output and quality. These offspring are used to supply
the global dairy and meat supply chain.


Genus' competitive edge has been created from the ownership and control of
proprietary lines of breeding animals, the biotechnology used to improve them
and the Group's global production and distribution network.


Headquartered in Basingstoke, England, Genus companies operate in 30 countries
on five continents, with research laboratories located in Madison, USA.





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
APPQVLFBVFBZBBQ

Genus (LSE:GNS)
Historical Stock Chart
From Jul 2024 to Aug 2024

Genus (LSE:GNS)
Historical Stock Chart
From Aug 2023 to Aug 2024